Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › belantamab mafodotin

belantamab mafodotin

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of belantamab mafodotin

5 trials tracked of belantamab mafodotin.

5Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 2
  1. Phase 2 Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) Completed
  2. Phase 2 Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma Completed
  3. Phase 2 To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Completed
  4. Phase 1 An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments Completed
  5. Phase 1 A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Drug Pipeline RCT
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
Blood Apr 17, 2026